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Treatment of refractory secondary hyperparathyroidism with been proposed as an alternative to surgery for these
ethanol injection: The importance of glandular volume. patients. Successful nodule destruction depends on sev-
Background. Percutaneous ethanol injection treatment eral factors, but the population eligible for treatment(PEIT) has been proposed as an alternative to surgery for
with PEIT has not been completely defined [6–13].patients with secondary hyperparathyroidism. The present
We report our experience with PEIT in patients withstudy was undertaken to determine factors that may predict
results. chronic renal failure and secondary hyperparathyroidism
Methods. We performed PEIT in 19 patients with secondary refractory to medical therapy. We analyze response to
hyperparathyroidism refractory to medical therapy under ul- treatment with relation to biochemical parameters, nod-trasonographic guidance in an ambulatory facility with local
ule characteristics, and technical aspects of the proce-anesthesia. Biochemical assays were performed immediately
dure.before the last dialysis session (basal) and between 1 to 7 days
after PEIT (post-PEIT).
Results. Serum PTH, calcium, and phosphorus levels de-
METHODScreased significantly after treatment. The percent of change in
serum PTH was significantly correlated to total nodular volume PEIT was performed in 19 patients with end-stage
(r  0.73, P  0.0004), and basal PTH levels (r  0.48, P 
renal disease (ESRD) and secondary hyperparathyroid-0.03). Post-PEIT serum phosphate and calcium x phosphate
ism refractory to medical therapy. All patients receivedproduct disclosed negative correlations that were statistically
significant with the decrease of PTH levels (r  0.60, P  hemodialysis three times a week, with a mean duration
0.009, and r0.60, P 0.01, respectively). The total nodular of 85.8  10.1 months of dialysis therapy.
volume was significantly correlated to the percent change in One patient had undergone subtotal parathyroidec-
serum calcium levels (r  0.60, P  0.01), in phosphate levels
tomy and suffered recurrent hyperparathyroidism in the(r  0.64, P  0.009), and calcium x phosphate product (r 
remaining portion of the gland. His clinical condition0.66, P  0.01).
Conclusion. Our findings suggest that patients with uncon- made him unsuitable for further surgery.
trolled secondary hyperparathyroidism may benefit from PEIT The criteria chosen to perform the treatment were:
if they present with very high basal PTH levels and/or big symptomatic bone disease associated to PTH levels
nodule size.
higher than 300 pg/mL, lack of responsiveness to cal-
citriol pulse therapy (either oral or intravenous), discon-
tinuation of calcitriol due to hypercalcemia (serum Ca
One of the main problems nephrologists face when
11 mg/dL), hyperphosphatemia (serum P 6 mg/dL),
treating chronic renal failure patients is to control the
or a calcium x phosphorous product higher than 65. The
increased secretion of parathyroid hormone during dial-
possibility of aluminum overload was ruled out by bone
ysis and after renal transplantation [1–5]. Great progress
biopsy, serum aluminum levels lower than 20 g/L, lack
has been achieved in this field in terms of medical ther-
of recent exposure to aluminum-containing phosphate
apy. However, there are still a large number of patients
binders, or to high levels of aluminum in the dialysate.
in whom the metabolic disorder cannot be controlled
The size of all glands treated with PEIT was larger than
and for whom parathyroidectomy is indicated.
0.1 cm3 as calculated by ultrasonographic evaluation of
Percutaneous ethanol injection treatment (PEIT) has
their three longest axes.
In those patients with extremely altered clinical and
biochemical features, a 99mTc Sestamibi scintigraphyKey words: PEIT, renal osteodystrophy, chronic renal failure, hemodi-
alysis. was performed to discard the presence of ectopic para-
thyroid tissue. 2003 by the International Society of Nephrology
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Table 1. Ultrasonographic, PEIT, and biochemical data
Ultrasonography and PEIT data MeanSE
Nodules/patient N 1.80.2
Total nodule size/patient cm3 1.50.4
Size/gland cm3 0.90.2
Injections/patient N 2.00.2
Ethanol volume/patient cm3 3.40.5
Biochemical data Basal MeanSE Post-PEIT MeanSE P value
PTH pg/mL 1184.5154.1 683.184.3 0.0002
Serum calcium mg/dL 10.50.4 9.30.4 0.02
Serum phosphate mg/dL 6.80.4 5.80.4 0.05
Calcium x phosphate product mg/dL2 70.84.2 53.54.5 0.02
Alkaline phosphatase UI/L 957.4286.3 1005.4314.4
PEIT was performed under ultrasonographic guidance The total nodular volume was significantly correlated
to the percent change of serum calcium levels (r  0.60,in an ambulatory facility. All injections were adminis-
tered by the same qualified interventional radiologist. A P 0.01), in phosphate levels (r 0.64, P 0.009) (Fig.
2 A and B), and calcium x phosphate products (r 0.66,95% ethanol solution was used for PEIT, with total alco-
hol volume calculated to be the same as the nodule P  0.01).
Ten of the 19 patients had only minor complicationsvolume. Local anesthesia with lidocaine was used. All
patients gave their informed consent to the procedure. related to PEIT; seven patients experienced neck dis-
comfort, which ceased immediately after the procedure.In each session one or more injections were performed
according to the anatomic characteristic of the glands. One patient developed minor hypocalcemia, but re-
sponded well to intravenous calcium administration. An-Biochemical assays were performed immediately be-
fore the last (basal) dialysis session and between 1 to 7 other patient reported a short duration of swallowing
discomfort, and another patient had a transient dys-days after the PEIT (post-PEIT).
Calcium, phosphorus, and alkaline phosphatase were phonia.
measured in an autoanalyzer (Hitachi 917; Hitachi, Ltd.,
Tokyo, Japan), and intact parathyroid hormone (PTH)
DISCUSSION
by electrochemiluminiscence (Nichol’s Institute, San Juan
The medical treatment of bone disease due to second-Capistrano, CA, USA).
ary hyperparathyroidism in patients with end-stage renalFor statistical analysis, Student t test for continuous
failure has recently improved [14–20]. However, in anvariables and Pearson correlation were used. P  0.05
important number of cases [21], this pathology is stillwas considered statistically significant.
problematic due to lack of responsiveness to therapy,
or, more frequently, discontinuation secondary to hyper-
RESULTS calcemia, hyperphosphatemia, or both. Surgical parathy-
roidectomy usually results in an immediate reductionTable 1 shows biochemical data and the number of
nodules per patient, the total nodule volume per patient, in parathyroid hormone levels, as well as clinical and
histologic bone improvement both short- and long-termthe number of injections per patient, and the alcohol
volume used for each nodule per patient. Thirty-four [22, 23]. Nonetheless, this kind of therapy is not com-
pletely safe. Besides the surgical risk these patients mayglands in 19 patients were treated by 38 sessions of PEIT.
There was a significant (33.3%  5.6%) decrease in present, there is also the possibility of recurrent hyper-
parathyroidism or, more frequently, the development ofPTH levels, from a mean of 1184.5 154.1 pg/mL (basal
PTH) to 683.1  84.3 (post-PEIT) (P  0.0002) (Table adynamic bone disease [24].
Since the early 1980s, PEIT has been proposed as a1), along with a decrease in serum levels of calcium and
phosphorous, and the calcium x phosphate product. less invasive alternative to parathyroidectomy, but re-
sults have not been always satisfactory. A possible reasonThe percent change in serum PTH was significantly
correlated to total nodular volume (r 0.73, P 0.0004), for this is that indications for this technique have not
been clearly established [6–13].and basal PTH levels (r 0.48, P 0.03) (Fig. 1 A and B).
Serum phosphate and calcium x phosphate products In this series we report a change in PTH and improve-
ment in serum calcium, phosphate, and calcium x phos-post-PEIT disclosed changes that were both negative
and significantly correlated to the decrease in PTH levels phate product, which was clearly correlated to basal PTH
levels and to nodule volume.(r  0.60, P  0.009 and r  0.60, P  0.01, respec-
tively). Patients with large nodule volume and very high basal
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Fig. 1. Correlation between percent reduc-
tion of PTH and (A) total nodular volume or
(B) basal PTH.
Fig. 2. Correlation between percent reduc-
tion of (A) calcium and (B) phosphate and
total nodular volume.
PTH levels were those who obtained the best results observed when parathyroid tissue of the previous size is
autografted after a total parathyroidectomy [25]. Thisafter PEIT.
Other researchers have obtained varying results. Ka- information is in agreement with our findings, since gland
size was an important factor in determining respon-kuta et al [10] obtained a decrease of more than 50%
in PTH levels in 80.4% of their patients. Giangrande et siveness to treatment. These results suggest that to obtain
a good response to PEIT, patients should have big nod-al [6, 7] found a similar decrease in 26% of their patients.
Such differences may be due to variations in patient ules and/or high basal PTH levels. Our experience con-
curs with Fukagawa et al [26] in that gland size is ancharacteristics, the PEIT technique, and PTH assays uti-
lized. important factor to consider when deciding upon the
management of parathyroid glands.Gland size is directly related to increased parathyroid
hormone secretion [11, 25]. It is possible that the better In this series, all responsive patients showed symptom-
atic clinical improvement almost immediately (data notresponse in patients with higher basal PTH levels and
larger glands was due to a better localization and opti- shown). As shown by Giangrande et al [7], all patients
with a positive symptomatic response to treatment pre-mized injection precision by ultrasonography [26]. The
larger size also may have helped achieve a better techni- sented an immediate decrease in PTH levels. An initial
PTH decrease was also evident in only 2 of 10 patientscal precision. Other groups have already pointed out the
importance of gland size [11, 25, 26]. It has been shown within the group of non-responsive patients. Our patients
showed significant improvement in calcemia, phos-that patients who have undergone parathyroidectomy
are more refractory to calcitriol pulse therapy when their phatemia, and calcium x phosphate product levels (Table
1), which allowed us to extend and intensify medicalglands are larger [25]. Also, it is important to consider
that the degree of hyperplasia is different in each patient therapy. A post-parathyroidectomy decrease of serum
phosphate has been described, especially in patients withand among the same patient’s four glands. Thus, it is
difficult to know exactly which gland or glands are affect- very high levels of PTH and alkaline phosphatase before
surgery. This may be related to the degree of severity ofing each patient, and to what extent each gland is af-
fected. More recently, the existing difficulties in achiev- osteitis fibrosa prior to the treatment [27]. The treatment
with phosphate binders and calcitriol was adequatelying a positive response to calcitriol in patients with gland
sizes larger than 0.5 to 1 cm or 0.5 cm3 have been de- continued in our responsive patients. This represents an
additional benefit of this technique.scribed [25]. A similar frequent recurrence rate has been
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10. Kakuta T, Fukagawa M, Fujisaki T, et al: Prognosis of parathyroidCONCLUSION
function after successful percutaneous ethanol injection therapy
guided by color doppler flow mapping in chronic renal failure. AmOur findings suggest that with the application of PEIT,
J Kidney Dis 33:1091–1099, 1999patients respond satisfactorily if they present with high
11. Kitaoka M, Fukagawa M, Ogata E, Kurokawa K: Reduction of
basal PTH levels and a considerable gland size. We pro- functioning parathyroid cell mass by ethanol injection in chronic
dialysis patients. Kidney Int 46:1110–1117, 1994pose to use it as a first step to control refractory second-
12. Cintin C, Karstrup S, Ladefoged S, Joffe P: Tertiary hyperpara-ary hyperparathyroidism. In other cases, the indications thyroidism treated by ultrasonically guided percutaneous fine-nee-
are less clear, but due to the low probability of complica- dle ethanol injection. Nephron 68:217–220, 1994
13. Fletcher S, Kanagasundaram N, Rayner H, et al: Assessmenttions, simplicity of the technique, and low cost, PEIT
of ultrasound guided percutaneous ethanol injection and parathy-should be considered when nodular parathyroid enlarge- roidectomy in patients with tertiary hyperparathyroidism. Nephrol
ment is found on ultrasonagraphic examination. Dial Transplant 13:3111–3117, 1998
14. Douthat W, Giraudo L, Aguirre E, et al: Eficacia y tolerancia
del acetato vs carbonato de calcio como quelantes del fosforo en
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